CA2616196C - A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor - Google Patents
A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor Download PDFInfo
- Publication number
- CA2616196C CA2616196C CA2616196A CA2616196A CA2616196C CA 2616196 C CA2616196 C CA 2616196C CA 2616196 A CA2616196 A CA 2616196A CA 2616196 A CA2616196 A CA 2616196A CA 2616196 C CA2616196 C CA 2616196C
- Authority
- CA
- Canada
- Prior art keywords
- pyridin
- methyl
- quinolin
- pyrrolo
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70164105P | 2005-07-22 | 2005-07-22 | |
| US60/701,641 | 2005-07-22 | ||
| PCT/US2006/025377 WO2007018818A1 (en) | 2005-07-22 | 2006-06-29 | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2616196A1 CA2616196A1 (en) | 2007-02-15 |
| CA2616196C true CA2616196C (en) | 2012-08-21 |
Family
ID=37450942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2616196A Expired - Fee Related CA2616196C (en) | 2005-07-22 | 2006-06-29 | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7872020B2 (https=) |
| EP (1) | EP1910370B1 (https=) |
| JP (1) | JP5242391B2 (https=) |
| BR (1) | BRPI0613639A2 (https=) |
| CA (1) | CA2616196C (https=) |
| DK (1) | DK1910370T3 (https=) |
| ES (1) | ES2542425T3 (https=) |
| HR (1) | HRP20150474T1 (https=) |
| HU (1) | HUE025209T2 (https=) |
| IL (1) | IL188181A (https=) |
| MX (1) | MX2008001020A (https=) |
| PL (1) | PL1910370T3 (https=) |
| PT (1) | PT1910370E (https=) |
| RS (1) | RS53999B1 (https=) |
| SI (1) | SI1910370T1 (https=) |
| WO (1) | WO2007018818A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR081810A1 (es) | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
| DK2731949T3 (en) * | 2011-07-13 | 2018-06-14 | Tiumbio Co Ltd | 2-PYRIDYL-SUBSTITUTED IMIDAZOLS AS ALK5 AND / OR ALK4 INHIBITORS |
| WO2014072517A1 (en) | 2012-11-12 | 2014-05-15 | Institució Catalana De Recerca I Estudis Avançats | Methods and kits for the prognosis of colorectal cancer |
| LT2970890T (lt) | 2013-03-14 | 2020-07-10 | The Brigham And Women`S Hospital, Inc. | Kompozicijos ir būdai, skirti epitelinių kamieninių ląstelių padauginimui ir kultivavimui |
| WO2016037016A1 (en) | 2014-09-03 | 2016-03-10 | The Brigham And Women's Hospital, Inc. | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
| HK1247861A1 (zh) | 2015-01-30 | 2018-10-05 | President And Fellows Of Harvard College | 用於癌症治疗的肿瘤周围和肿瘤内部材料 |
| ES2918924T3 (es) | 2015-04-01 | 2022-07-21 | Rigel Pharmaceuticals Inc | Inhibidores de TGF-beta |
| US10669528B2 (en) | 2015-06-25 | 2020-06-02 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| KR102738306B1 (ko) | 2015-12-15 | 2024-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | Cxcr4 수용체 길항제 |
| CN108779437A (zh) | 2016-01-08 | 2018-11-09 | 麻省理工学院 | 分化的肠内分泌细胞和胰岛素产生细胞的制备 |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| WO2017161001A1 (en) | 2016-03-15 | 2017-09-21 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| CN109548403A (zh) | 2016-07-07 | 2019-03-29 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| EP3527570A4 (en) | 2016-10-14 | 2020-04-15 | Jiangsu Hengrui Medicine Co., Ltd. | FIVE-LINKED HETERARYARYLE CYCLE BRIDGE DERIVATIVE, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF |
| US11066419B2 (en) | 2016-12-30 | 2021-07-20 | Frequency Therapeutics, Inc. | 1H-pyrrole-2,5-dione compounds and methods of using same |
| CN110582497B (zh) * | 2017-03-17 | 2022-03-11 | 杭州领业医药科技有限公司 | Galunisertib的晶型及其制备方法和药物组合物 |
| US10995083B2 (en) | 2017-03-21 | 2021-05-04 | Hangzhou Solipharma Co., Ltd. | Cocrystal of 2-(6-methyl-pyridine-2-yl)-3-yl-[6-amide-quinoline-4-yl]-5,6-dihydro-4H-pyrrole[1,2-b]pyrazole, preparation method therefor, and pharmaceutical composition |
| WO2019042383A1 (zh) * | 2017-08-31 | 2019-03-07 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| WO2019105082A1 (zh) * | 2017-11-30 | 2019-06-06 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| WO2019137027A1 (zh) * | 2018-01-12 | 2019-07-18 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| JP2021518413A (ja) | 2018-03-20 | 2021-08-02 | アイカーン スクール オブ メディシン アット マウント サイナイ | キナーゼ阻害剤化合物及び組成物ならびに使用方法 |
| US20210254006A1 (en) | 2018-06-06 | 2021-08-19 | Ideaya Biosciences, Inc. | Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds |
| CN113195707A (zh) | 2018-08-17 | 2021-07-30 | 频率治疗公司 | 用于通过上调jag-1来生成毛细胞的组合物和方法 |
| US11617745B2 (en) | 2018-08-17 | 2023-04-04 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating FOXO |
| WO2020142485A1 (en) | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| CN115282280A (zh) * | 2022-08-12 | 2022-11-04 | 中国科学技术大学 | TGF-β1信号抑制剂的新用途 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| GB202309553D0 (en) | 2023-06-24 | 2023-08-09 | Ucl Business Ltd | Compostions and uses thereof |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1397364B1 (en) * | 2001-05-24 | 2007-07-25 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
| CA2506799A1 (en) | 2002-11-21 | 2004-06-10 | Eli Lilly And Company | Mixed lineage kinase modulators |
| UA80571C2 (en) * | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
-
2006
- 2006-06-29 EP EP20060774280 patent/EP1910370B1/en active Active
- 2006-06-29 WO PCT/US2006/025377 patent/WO2007018818A1/en not_active Ceased
- 2006-06-29 HU HUE06774280A patent/HUE025209T2/en unknown
- 2006-06-29 JP JP2008522796A patent/JP5242391B2/ja not_active Expired - Fee Related
- 2006-06-29 SI SI200631924T patent/SI1910370T1/sl unknown
- 2006-06-29 HR HRP20150474TT patent/HRP20150474T1/hr unknown
- 2006-06-29 ES ES06774280.9T patent/ES2542425T3/es active Active
- 2006-06-29 RS RS20150319A patent/RS53999B1/sr unknown
- 2006-06-29 PT PT67742809T patent/PT1910370E/pt unknown
- 2006-06-29 PL PL06774280T patent/PL1910370T3/pl unknown
- 2006-06-29 BR BRPI0613639-7A patent/BRPI0613639A2/pt not_active Application Discontinuation
- 2006-06-29 US US11/995,938 patent/US7872020B2/en not_active Expired - Fee Related
- 2006-06-29 DK DK06774280.9T patent/DK1910370T3/en active
- 2006-06-29 CA CA2616196A patent/CA2616196C/en not_active Expired - Fee Related
- 2006-06-29 MX MX2008001020A patent/MX2008001020A/es active IP Right Grant
-
2007
- 2007-12-17 IL IL188181A patent/IL188181A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20100120854A1 (en) | 2010-05-13 |
| JP5242391B2 (ja) | 2013-07-24 |
| CA2616196A1 (en) | 2007-02-15 |
| PL1910370T3 (pl) | 2015-09-30 |
| US7872020B2 (en) | 2011-01-18 |
| DK1910370T3 (en) | 2015-06-08 |
| WO2007018818A1 (en) | 2007-02-15 |
| EP1910370A1 (en) | 2008-04-16 |
| BRPI0613639A2 (pt) | 2012-02-22 |
| PT1910370E (pt) | 2015-06-30 |
| JP2009502780A (ja) | 2009-01-29 |
| ES2542425T3 (es) | 2015-08-05 |
| MX2008001020A (es) | 2008-03-25 |
| IL188181A (en) | 2014-05-28 |
| HRP20150474T1 (xx) | 2015-06-05 |
| EP1910370B1 (en) | 2015-04-22 |
| SI1910370T1 (sl) | 2015-06-30 |
| HUE025209T2 (en) | 2016-03-29 |
| IL188181A0 (en) | 2008-03-20 |
| RS53999B1 (sr) | 2015-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2616196C (en) | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor | |
| EP3037424B1 (en) | Novel quinoline-substituted compound | |
| AU2016288204B2 (en) | Inhibitors of EGFR and methods of use thereof | |
| AU2015330506B2 (en) | EGFR inhibitor, and preparation and application thereof | |
| AU2008252380B2 (en) | Quinazolin-oxime derivatives as Hsp90 inhibitors | |
| JP2015180679A (ja) | ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形 | |
| EP2985277A1 (en) | Dipyrromethene crystal and method for manufacturing same | |
| SK9622000A3 (en) | Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas | |
| AU2008208801A1 (en) | Purine derivatives | |
| AU2012291041A1 (en) | Uracil derivative and use thereof for medical purposes | |
| HUE029343T2 (en) | Quinolylpyrrolo-pyrimidyl fused ring compounds and salts thereof | |
| CA3149846A1 (en) | Quinoline derivatives as protein kinase inhibitors | |
| CN111542522B (zh) | 可用作激酶抑制剂的被取代的吡唑并嘧啶 | |
| UA54449C2 (uk) | 3-заміщені похідні піридо[4',3':4,5]тієно[2,3-d]піримідину | |
| EP3434674B1 (en) | ((4-(2-oxoimidazolidine-1-yl)pyrimidin-2-yl)amine derivatives as mutant idh inhibitors for treating cancer | |
| CN112823159B (zh) | 一类具有激酶抑制活性的芳香杂环类化合物 | |
| CN117800953A (zh) | 一种2-芳香胺基嘧啶类化合物及其制备方法与应用 | |
| KR101859170B1 (ko) | 트리아졸 화합물 및 이의 용도 | |
| CN118251400A (zh) | Axl激酶抑制剂的盐、其制备方法和用途 | |
| WO2014020531A1 (en) | Imidazo[1,2-b]pyridazin-6-amine derivatives as kinase jak-2 inhibitors | |
| HK1256370B (en) | 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer | |
| HK1256370A1 (en) | 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer | |
| PL167014B1 (pl) | Sposób wytwarzania nowych pochodnych azolu |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20200831 |